In yesterday’s Wall Street session, POINT Biopharma Global Inc (NASDAQ:PNT) shares traded at $13.33, down -0.52% from the previous session.
As of this writing, 11 analysts cover POINT Biopharma Global Inc (NASDAQ:PNT). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $27.00 and a low of $12.50, we find $12.50. Given the previous closing price of $13.40, this indicates a potential downside of -6.72 percent. PNT stock price is now 23.88% away from the 50-day moving average and 48.22% away from the 200-day moving average. The market capitalization of the company currently stands at $1.42B.
There are 8 analysts who have given it a hold rating, whereas 3 have given it a buy rating. Brokers who have rated the stock have averaged $14.50 as their price target over the next twelve months.
In other news, MCCANN JOE A., Chief Executive Officer bought 2,160 shares of the company’s stock on Nov 29. The stock was bought for $14,342 at an average price of $6.64. Upon completion of the transaction, the Chief Executive Officer now directly owns 3,616,313 shares in the company, valued at $48.21 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 28, Director Malik Rajesh bought 3,700 shares of the business’s stock. A total of $24,642 was incurred on buying the stock at an average price of $6.66. This leaves the insider owning 3,700 shares of the company worth $49321.0. Insiders disposed of 250,000 shares of company stock worth roughly $3.33 million over the past 1 year. A total of 17.83% of the company’s stock is owned by insiders.
Thursday morning saw POINT Biopharma Global Inc (NASDAQ: PNT) opened at $13.33. During the past 12 months, POINT Biopharma Global Inc has had a low of $5.95 and a high of $13.55. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 9.14, and a quick ratio of 9.14. The fifty day moving average price for PNT is $10.76 and a two-hundred day moving average price translates $8.99 for the stock.
The latest earnings results from POINT Biopharma Global Inc (NASDAQ: PNT) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.23, beating analysts’ expectations of -$0.3 by 0.07. This compares to -$0.26 EPS in the same period last year. The net profit margin was 39.62% and return on equity was 26.33% for PNT. For the current quarter, analysts expect PNT to generate $1.36M in revenue.
POINT Biopharma Global Inc(PNT) Company Profile
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.